A Guide for Selection of Genetic Instruments in Mendelian Randomization Studies of Type 2 Diabetes and HbA1c: Toward an Integrated Approach
Open Access
- 20 January 2023
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 72 (2) , 175-183
Abstract
In this study we examine the instrument selection strategies currently used throughout the type 2 diabetes and HbA1c Mendelian randomization (MR) literature. We then argue for a more integrated and thorough approach, providing a framework to do this in the context of HbA1c and diabetes. We conducted a literature search for MR studies that have instrumented diabetes and/or HbA1c. We also used data from the UK Biobank (UKB) (N = 349,326) to calculate instrument strength metrics that are key in MR studies (the F statistic for average strength and R2 for total strength) with two different methods (“individual-level data regression” and Cragg-Donald formula). We used a 157–single nucleotide polymorphism (SNP) instrument for diabetes and a 51-SNP instrument (with partition into glycemic and erythrocytic as well) for HbA1c. Our literature search yielded 48 studies for diabetes and 22 for HbA1c. Our UKB empirical examples showed that irrespective of the method used to calculate metrics of strength and whether the instrument was the main one or included partition by function, the HbA1c genetic instrument is strong in terms of both average and total strength. For diabetes, a 157-SNP instrument was shown to have good average strength and total strength, but these were both substantially lesser than those of the HbA1c instrument. We provide a careful set of five recommendations to researchers who wish to genetically instrument type 2 diabetes and/or HbA1c. In MR studies of glycemia, investigators should take a more integrated approach when selecting genetic instruments, and we give specific guidance on how to do this.Keywords
All Related Versions
Funding Information
- Wellcome Trust
- Diabetes UK
- UK Medical Research Council (MC_ST_LHA_2019, MC_UU_0019/2)
- AstraZeneca
- Royal Society (204623/Z/16/Z)
- British Heart Foundation (15/0005250)
- Biomedical Research Centre (BRC-1215-20014)
- National Institute for Health Research
- UK Biobank
This publication has 83 references indexed in Scilit:
- Type 2 Diabetes, Diabetes Genetic Score and Risk of Decreased Renal Function and Albuminuria: A Mendelian Randomization StudyEBioMedicine, 2016
- Diabetes and Risk of Arterial Stiffness: A Mendelian Randomization AnalysisDiabetes, 2016
- Diabetic Phenotypes and Late-Life Dementia RiskAlzheimer Disease & Associated Disorders, 2016
- A Mendelian randomization study of the effect of type-2 diabetes on coronary heart diseaseNature Communications, 2015
- Mendelian randomization studies: a review of the approaches used and the quality of reportingInternational Journal of Epidemiology, 2015
- UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old AgePLOS Medicine, 2015
- Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibilityNature Genetics, 2014
- Avoiding bias from weak instruments in Mendelian randomization studiesInternational Journal of Epidemiology, 2011
- Mendelian randomization: prospects, potentials, and limitationsInternational Journal of Epidemiology, 2004
- ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?*International Journal of Epidemiology, 2003